- Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients2021 | Lékařská fakulta v Plzni, 1. lékařská fakulta
- Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial2019 | Publikace bez příslušnosti k fakultě
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial2019 | Publikace bez příslušnosti k fakultě
- How Many Measurements Are Needed to Estimate Blood Pressure Variability Without Loss of Prognostic Information?2014 | Lékařská fakulta v Plzni
- Ambulatory Hypertension Subtypes and 24-Hour Systolic and Diastolic Blood Pressure as Distinct Outcome Predictors in 8341 Untreated People Recruited From 12 Populations2014 | Lékařská fakulta v Plzni
- Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial2019 | Publikace bez příslušnosti k fakultě
- Predictive power of 24-h ambulatory pulse pressure and its components for mortality and cardiovascular outcomes in 11 848 participants recruited from 13 populations2022 | Lékařská fakulta v Plzni
- Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes2011 | Ústřední knihovna